SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Shiratori Y, Shiina S, Imamura M et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22: 102733.
  • 2
    Benvegnu L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 24428.
  • 3
    Bruno S, Silini E, Crosignani A et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 7548.
  • 4
    Ikda K, Saitoh S, Suzuki Y et al. Diseases progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J. Hepatol. 1998; 28: 9308.
  • 5
    Khan MH, Farrell GC, Byth K et al. Which patients with chronic hepatitis C develop liver complications? Hepatology 2000; 31: 51320.
  • 6
    Hirashima N, Matsumoto Y, Ohono T et al. Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy. J. Clin. Gastroenterol. 2002; 34: 2637.
  • 7
    Yoneyama K, Yamaguchi M, Kiuchi Y et al. Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon. Intervirology 2002; 45: 1119.
  • 8
    Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 112430.
  • 9
    Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka liver disease study group. Hepatology 1998; 27: 1394402.
  • 10
    Okanoue T, Itoh Y, Minami M et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral hepatitis therapy study group. J. Hepatol. 1999; 30: 6539.
  • 11
    Okanoue T, Itoh Y, Kirishima T et al. Transient biochemical response in interferon therapy decreases the development of hepatocelllar carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol. Res. 2002; 23: 6277.
  • 12
    Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduced the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann. Intern. Med. 1999; 131: 17481.
  • 13
    Tanaka H, Tsukuma H, Kasahara A et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int. J. Cancer 2000; 87: 7419.
  • 14
    Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol. 1996; 24: 1417.
  • 15
    Fattovich G, Giustina G, Realdi G et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 133842.
  • 16
    International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351: 15359.
  • 17
    Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 9715.
  • 18
    Miyano S, Togashi H, Shinzawa H et al. Case report: occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J. Gastroenterol. Hepatol. 1999; 14: 92830.
  • 19
    Yamaguchi K, Omagari K, Kinoshita H et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. J. Clin. Gastroenterol. 1999; 29: 2079.
  • 20
    Toyoda H, Kumada T, Tokuda A et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J. Viral. Hepat. 2000; 7: 41419.
  • 21
    Yamaura T, Matsumoto A, Rokuhara A et al. Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy. J. Gastroenterol. Hepatol. 2002; 17: 122935.
  • 22
    Okamura K, Yamazaki K, Ohmura T et al. [A resected case of hepatocellular carcinoma with sustained response to interferon for five years.] Acta Hepatol. Jpn 2000; 41: 437. (In Japanese.)
  • 23
    Sugo H, Kitayama N, Iwata T et al. [Development of hepatocellular carcinoma in a patient with chronic hepatitis C after a complete response to interferon therapy. Acta Hepatol. Jpn 2000; 41: 1958. (In Japanese.)
  • 24
    Toyoda H, Kumada T, Honda T et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2001; 16: 11317.
  • 25
    Kenmochi K, Sugihara S, Kojiro M. Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. Liver 1987; 7: 1826.
  • 26
    Sugihara S, Nakashima O, Kojiro M et al. The morphologic transition in hepatocellular carcinoma. A comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer 1992; 70: 148892.
  • 27
    Majima Y. [Growth rate of hepatocellular carcinoma by ultrasonography and it's clinical significance.] Acta Hepatol. Jpn 1984; 25: 75465. (In Japanese.)
  • 28
    Saitoh S, Ikeda K, Koida I et al. Serial hemodynamic measurement in well-differentiated hepatocellular carcinoma. Hepatology 1995; 21: 15304.
  • 29
    Ebara M, Ohto M, Shinagawa T et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis, a study in 22 patients. Gastroenterology 1986; 90: 28998.
  • 30
    Barbara L, Benzi G, Gaiani S et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 1327.